DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results
- 39% year-over-year growth in core B2B2C business.
- Signed multiple customers onto the Aetna platform.
- Expected enhancement of profitability and revenue scale through the acquisition of Twill, Inc.
- Decrease in full-year 2023 revenue compared to 2022.
- Gross profit decrease for Q4 2023.
- Increase in total operating expenses for Q4 2023.
Insights
The shift in revenue streams from B2C to B2B2C is a strategic move that aligns with current market trends, where businesses increasingly seek to leverage existing customer bases of other businesses to grow their own. This pivot has allowed the company to tap into recurring revenue models, which are typically more stable and predictable than one-time sales, leading to a 39% year-over-year increase in B2B2C revenue. The decrease in GAAP and non-GAAP operating expenses indicates improved operational efficiency, which is vital for long-term sustainability. The acquisition of Twill, Inc., suggests a strategic expansion and diversification of offerings, which could potentially open up new revenue channels and customer segments.
The company's focus on increasing the lifetime value of members and achieving cost synergies could drive profitability. However, the reported net losses and the decrease in gross profit percentage raise concerns about current profitability levels. Investors should monitor the integration of Twill and the realization of projected cost synergies, as these factors will be critical in determining the company's financial health and stock performance in the future.
The reported decrease in full-year revenue alongside a reduction in operating expenses suggests a period of transition for the company, with a potential focus on profitability over top-line growth. The reported increase in B2B2C revenue is a positive indicator of the company's strategic shift paying off, but the overall decline in revenue and gross profit raises questions about the immediate financial impact of this strategy. The strong cash position at year-end, bolstered by the recent financing, provides a cushion for the company's operations and strategic initiatives. However, the significant net loss reported indicates ongoing challenges to achieving profitability.
Investors should consider the company's trajectory towards profitability, the successful integration of Twill and the ability to realize the anticipated gross margins greater than 80% by 2025. The company's pro forma non-audited revenues and expected cost synergies from the acquisition are promising, but actual performance against these projections will be key for investor confidence.
The digital health sector is rapidly evolving and the company's strategic pivot to focus on the B2B2C model reflects an understanding of the importance of recurring revenue from employers and health plans. The adoption of the Dario GLP-1 Behavioral Change Program and the expansion of customer relationships on the metabolic side indicate a strong product-market fit in the chronic condition management space, which is a growing segment in healthcare. The acquisition of Twill is poised to enhance the company's digital health offerings and customer base, which could lead to increased market share.
However, the reduction in gross profit percentage and the significant operating loss suggest that while the company is gaining traction in its core areas, there is still work to be done in achieving profitability. The company's future success will likely hinge on its ability to effectively integrate Twill's offerings, achieve the anticipated cost synergies and continue to grow its B2B2C revenue stream.
- Full-year 2023 revenue of
$20.4 million $7.3 - 2023 B2B2C, employers and health plans recurring revenues increased
39% year over year as the core business continues to gain traction. - Commercial revenues in 2023 generated majority of the revenue with B2B2C growing from
13% to25% of total revenue from 2022 to 2023. - GAAP operating expenses decreased by
11.2% sequentially from the third quarter of 2023. - Non-GAAP operating expenses decreased
9.4% sequentially from the third quarter to$9.9M - Signed multiple customers onto the Aetna platform which subsequently launched in Q1 of 2024.
- Saw significant interest and multiple employer adoption of the Dario GLP-1 Behavioral Change Program as well as expansions of current customer relationships on the metabolic side.
- Enhanced path to profitability through improvements across the financial profile on an annual basis, which we expect will continue into 2024 and accelerate with the acquisition of Twill, Inc. in Q1 of 2024.
- Total pro forma non-audited revenues of approximately
$38 million - Ended 2023 with cash equivalents of
$37 million $22.4 million - Company to host investor conference call and webcast at 8:30 a.m. ET today.
"2023 was a very significant year for Dario. Our financial profile continued to improve as a result of our pivot to a Business-to-Business-to-Consumer (B2B2C) business model with growing B2B2C revenue and decreasing operating costs. As we have previously discussed, our revenue comes from three sources; our historical direct to consumer/business to consumer (B2C) business, recurring revenue from health plans and employers (B2B2C), and strategic revenue from partners like Sanofi
"Last month we announced the transformational acquisition of Twill, Inc. ("Twill") accompanied by a
- Creation of one of the most comprehensive digital health offerings spanning from emotional well-being through some of the costliest chronic conditions.
- Nearly doubles non-audited pro forma 2023 revenue with approximately
$38 million - The addition of high gross margin revenue that, when combined with Dario's existing business, is expected to enable the company to reach margins greater than
80% by 2025. - Ability to leverage Twill's innovative approaches to engagement and navigation and breadth of offering to increase sales opportunities, revenue per customer and lifetime value of members.
- Expected ability to achieve
30% annualized cost synergies within two years. - Addition of high value non-overlapping customers in Dario's core health plan and employer markets, which enables significant opportunities for cross selling.
- An accelerated path to profitability expected in 2025 through revenue scale, increased gross margins and cost synergies.
Following the recent acquisition of Twill, we have commenced selling our new combined offerings and the have begun the integration process and expect to report outcomes in the coming quarters. We believe that this acquisition completely transforms Dario and firmly establishes it as one of the leaders in the space, that understands how to leverage organic and inorganic growth to improve financial metrics and manage responsible growth. We ended the year with a strong cash position of
"We were pleased to conclude the employer sales season in the fourth quarter and continue to see increasing traction across all of our sales channels. We expect to continue to grow revenue in our core B2B2C business with the launch of the most significant number of new customers on our platform in the first quarter of 2024. Adding to these new customers, the Aetna platform launched with several customers in January and has continued to add customers that are planned for launches through second quarter of 2024. The separate self-help business we won from Aetna will also launch at the beginning of the second quarter of 2024. We have already seen a strong start to the 2024 employer sales cycle with larger opportunities compared to 2023. We anticipate additional health plan customers this year directly and through our partners that cover more than 87 million members," stated Rick Anderson, President of Dario. "In addition, Twill's existing pipeline adds millions of dollars of sales opportunities, several that are late stage or are in contracting. Excitingly, customers from both companies have expressed a strong interest in exploring opportunities created by the combination of the products and we look forward to strong cross selling opportunities."
Q4 2023 and Recent Highlights
- Completed the transformational acquisition of Twill in Q1 of 2024 concurrent with a
$22.4 million - Made meaningful progress in multiple areas with the new Dario GLP-1 Behavioral Change Program. We saw significant interest and adoption of the program across existing commercial clients as well as a new national employer and regional union.
- Launched more than a dozen new customers and partners on the platform in the first quarter of 2024, with additional recently signed customers expected to launch in the second quarter of 2024.
- Launched the Aetna private labeled platform in Q1 of 2024, with multiple employer groups and have seen additional Aetna customer bookings in the first quarter of 2024.
- Agreed with multiple customers, including two of our health plans, to expand their population on the platform.
- Announced a new strategic partnership with a top five national employee benefits consulting firm to become the preferred digital health and chronic condition solution partner for its national employer clients. The partnership includes Dario's solutions for diabetes, pre-diabetes, hypertension, musculoskeletal and behavioral health.
- Announced new research presented by Sanofi at the Academy of Managed Care Pharmacy's 2023 annual conference Nexus demonstrating a
36% reduction in 30-day hospital readmissions for Dario users compared to non-users living with type 2 diabetes. - Announced new research presented at the Diabetes Technology Society 2023 Meeting demonstrating the quantifiable value of associating physical activity tracking alongside blood sugar tracking for people living with diabetes and pre-diabetes.
- Announced two new analyses presented by Sanofi at the Diabetes Technology Society (DTS) annual conference demonstrating two mediators associated with improved clinical and economic in Dario users who saw an overall clinically significant reduction in HbA1c, improvement in medication adherence, reduction in all-cause healthcare resource use, and less likelihood of incurring related charges.
- Continued to demonstrate the strength of Dario's multi-condition suite, with more than
80% of pipeline opportunities for multi-condition contracts.
Fourth Quarter 2023 Results Summary
Revenues for the fourth quarter ended December 31, 2023, were
Gross profit for the fourth quarter of 2023 was
Pro-forma gross profit, excluding
Total operating expenses for the fourth quarter ended December 31, 2023, were
Operating loss for the fourth quarter of 2023 was
Net loss was
Net loss excluding stock-based compensation, acquisition related expenses and depreciation for the fourth quarter of 2023, was
Non-GAAP billings for the three months ended December 31, 2023, were
Full Year 2023 Results Summary
Revenues for the twelve months ended December 31, 2023, were
Gross profit for the twelve months ended December 31, 2023, was
Pro-forma gross profit, excluding
Total operating expenses for the twelve months ended December 31, 2023, were
Operating loss for the twelve months ended December 31, 2023, decreased by
Net loss was
Non-GAAP billings for the twelve months ended December 31, 2023, were
Non-GAAP adjusted operating loss for the twelve months ended December 31, 2023, was
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Conference Call Details: Thursday, March 28, 8:30am ET
Date: Thursday, March 28th, 8:30am ET
Dial-in Number: 1-888-886-7786 (domestic) or 1-416-764-8658 (international)
Call me™: https://emportal.ink/3T9QM65
Participants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to scheduled start time.
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1659828&tp_key=33195a8703
Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion through Sunday, April 28th, 2024. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 63790103.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Our user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of the Company related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, when the Company discusses the potential benefits of the Twill acquisition, including the expected doubling of non-audited pro forma revenue, that it expects margins greater than
Non-GAAP Financial Measures
We have provided in this release financial information that has not been prepared in accordance with Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. We use these non-GAAP financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to GAAP measures, in evaluating our ongoing operational performance. We believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with peer companies, many of which present similar non-GAAP financial measures to investors.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures provided in the financial statement tables below.
Billings (non-GAAP). We define billings as revenue recognized in accordance with GAAP plus the change in deferred revenue from the beginning to the end of the period and adjustment to the deferred revenue balance due to adoption of the new revenue recognition standard less any deferred revenue balances acquired from business combination(s) during the period. We consider billings to be a useful metric for management and investors because billings drive future revenue, which is an important indicator of the health and viability of our business. There are a number of limitations related to the use of billings instead of GAAP revenue. First, billings include amounts that have not yet been recognized as revenue and are impacted by the term of security and support agreements. Second, we may calculate billings in a manner that is different from peer companies that report similar financial measures. Management accounts for these limitations by providing specific information regarding GAAP revenue and evaluating billings together with GAAP revenue.
Operating expenses (non-GAAP). Our presentation of non-GAAP operating expenses excludes stock-based compensation expenses, depreciation of fixed assets, earn-out remeasurement and acquisition related expenses and amortization. Due to varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash operating expenses, we believe that providing non-GAAP financial measures that exclude non-cash expense provides us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.
Net loss (non-GAAP). Our presentation of adjusted net loss excludes the effect of certain items that are non-GAAP financial measures. Adjusted net loss represents net loss determined under GAAP without regard to stock-based compensation expenses, deferred inventory, depreciation of fixed assets, earn-out remeasurement and acquisition related expenses and amortization. We believe these measures provide useful information to management and investors for analysis of our operating results.
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | |||||||
CONSOLIDATED BALANCE SHEETS | |||||||
December 31, | |||||||
2023 | 2022 | ||||||
ASSETS | |||||||
CURRENT ASSETS: | |||||||
Cash and cash equivalents | $ | 36,797 | $ | 49,357 | |||
Short-term restricted bank deposits | 292 | 165 | |||||
Trade receivables, net | 3,155 | 6,416 | |||||
Inventories | 5,062 | 7,956 | |||||
Other accounts receivable and prepaid expenses | 2,024 | 1,630 | |||||
Total current assets | 47,330 | 65,524 | |||||
NON-CURRENT ASSETS: | |||||||
Deposits | 6 | 6 | |||||
Operating lease right of use assets | 967 | 1,206 | |||||
Long-term assets | 143 | 111 | |||||
Property and equipment, net | 899 | 788 | |||||
Intangible assets, net | 5,404 | 9,916 | |||||
Goodwill | 41,640 | 41,640 | |||||
Total non-current assets | 49,059 | 53,667 | |||||
Total assets | $ | 96,389 | $ | 119,191 | |||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
CONSOLIDATED BALANCE SHEETS | ||||||
December 31, | ||||||
2023 | 2022 | |||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
CURRENT LIABILITIES: | ||||||
Trade payables | $ | 1,131 | $ | 2,322 | ||
Deferred revenues | 997 | 1,320 | ||||
Operating lease liabilities | 111 | 293 | ||||
Other accounts payable and accrued expenses | 6,300 | 6,592 | ||||
Current maturity of long term loan | 3,954 | 8,823 | ||||
Total current liabilities | 12,493 | 19,350 | ||||
NON-CURRENT LIABILITIES | ||||||
Operating lease liabilities | 885 | 827 | ||||
Long-term loan | 24,591 | 18,105 | ||||
Warrant liability | 240 | 910 | ||||
Other long-term liabilities | 36 | — | ||||
Total non-current liabilities | 25,752 | 19,842 | ||||
STOCKHOLDERS' EQUITY | ||||||
Common stock of | 3 | 3 | ||||
Preferred stock of | *) - | *) - | ||||
Additional paid-in capital | 407,502 | 365,846 | ||||
Accumulated deficit | (349,361) | (285,850) | ||||
Total stockholders' equity | 58,144 | 79,999 | ||||
Total liabilities and stockholders' equity | $ | 96,389 | $ | 119,191 | ||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS | ||||||
Year ended | ||||||
December 31, | ||||||
2023 | 2022 | |||||
Revenues: | ||||||
Services | $ | 13,084 | $ | 17,859 | ||
Consumer hardware | 7,268 | 9,797 | ||||
Total revenues | 20,352 | 27,656 | ||||
Cost of revenues: | ||||||
Services | 4,679 | 5,324 | ||||
Consumer hardware | 5,303 | 8,320 | ||||
Amortization of acquired intangible assets | 4,386 | 4,357 | ||||
Total cost of revenues | 14,368 | 18,001 | ||||
Gross profit | 5,984 | 9,655 | ||||
Operating expenses: | ||||||
Research and development | $ | 20,248 | $ | 19,649 | ||
Sales and marketing | 23,785 | 30,323 | ||||
General and administrative | 18,140 | 16,493 | ||||
Total operating expenses | 62,173 | 66,465 | ||||
Operating loss | 56,189 | 56,810 | ||||
Total financial expenses, net | 3,174 | 5,379 | ||||
Loss before taxes | 59,363 | 62,189 | ||||
Income Tax | 64 | 4 | ||||
Net loss | $ | 59,427 | $ | 62,193 | ||
Deemed dividend | $ | 4,084 | $ | 1,643 | ||
Net loss attributable to shareholders | $ | 63,511 | $ | 63,836 | ||
Net loss per share: | ||||||
Basic and diluted loss per share of common stock | $ | 1.93 | $ | 2.54 | ||
Weighted average number of common stock used in computing | 28,371,979 | 23,635,038 | ||||
DARIOHEALTH CORP. AND ITS SUBSIDIARIES | ||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
Year ended | ||||||
December 31, | ||||||
2023 | 2022 | |||||
Cash flows from operating activities: | ||||||
Net loss | $ | (59,427) | $ | (62,193) | ||
Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||
Stock-based compensation, common stock, and payment in stock to directors, | 19,701 | 16,975 | ||||
Depreciation | 473 | 356 | ||||
Change in operating lease right of use assets | 239 | (919) | ||||
Amortization of acquired intangible assets | 4,512 | 4,361 | ||||
Decrease (increase) in trade receivables | 3,261 | (5,106) | ||||
Increase in other accounts receivable, prepaid expense and long-term assets | (426) | (3) | ||||
Decrease (increase) in inventories | 2,894 | (1,728) | ||||
Decrease in trade payables | (1,191) | (2,787) | ||||
Decrease in other accounts payable and accrued expenses | (256) | (1,314) | ||||
Increase (Decrease) in deferred revenues | (323) | 125 | ||||
Change in operating lease liabilities | (124) | 833 | ||||
Remeasurement of earn-out | - | (497) | ||||
Non cash financial expenses | 528 | 4,052 | ||||
Other | (240) | — | ||||
Net cash used in operating activities | (30,379) | (47,845) | ||||
Cash flows from investing activities: | ||||||
Purchase of property and equipment | (584) | (442) | ||||
Purchase of short-term investments | (4,996) | - | ||||
Proceeds from redemption of short-term investments | 5,033 | - | ||||
Purchase of intangible assets | - | (131) | ||||
Net cash used in investing activities | (547) | (573) | ||||
Cash flows from financing activities: | ||||||
Proceeds from issuance of common stock and prefunded warrants, net of issuance costs | 1,614 | 38,288 | ||||
Proceeds from issuance of preferred stock, net of issuance costs | 14,868 | - | ||||
Proceeds from borrowings on Loan agreement | 29,604 | 23,786 | ||||
Repayment of long-term loan | (27,833) | — | ||||
Repurchase and retirement of common stock | — | (134) | ||||
Net cash provided by financing activities | 18,253 | 61,940 | ||||
Increase in cash, cash equivalents and restricted cash and cash equivalents | (12,673) | 13,522 | ||||
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | 49,470 | 35,948 | ||||
Cash, cash equivalents and restricted cash and cash equivalents at end of period | 36,797 | 49,470 | ||||
Supplemental disclosure of cash flow information: | ||||||
Cash paid during the period for interest on long-term loan | 4,031 | 1,876 | ||||
Non-cash activities: | ||||||
Right-of-use assets obtained in exchange for lease liabilities | 136 | 1,269 | ||||
Earn-out extinguishment as part of WayForward acquisition | - | 328 | ||||
Reconciliation of Revenue to Billing (Non-GAAP) | ||||||||
Three Months Ended December 31, | Twelve Months Ended December 31, | |||||||
2023 | 2022 | 2023 | 2022 | |||||
GAAP Revenue | 20,352 | 27,656 | 3,616 | 6,809 | ||||
Add: | ||||||||
Change in deferred revenue | (323) | 125 | 313 | 330 | ||||
Billing (Non-GAAP) | 20,029 | 27,781 | 3,929 | 7,139 | ||||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Three months ended December 31, 2023 | ||||||||
GAAP | Stock-Based | Acquisition costs, | Non-GAAP | |||||
Cost of Revenues | $ | 3,484 | (266) | (1,118) | 2,100 | |||
Gross Profit | 132 | 266 | 1,118 | 1,516 | ||||
Research and development | 4,196 | (90) | (21) | 4,085 | ||||
Sales and Marketing | 4,622 | (918) | (42) | 3,662 | ||||
General and Administrative | 5,529 | (3,120) | (267) | 2,142 | ||||
Total Operating Expenses | 14,347 | (4,128) | (330) | 9,889 | ||||
Operating Loss | $ | (14,215) | 4,394 | 1,448 | (8,373) | |||
Financing expenses | 6 | - | - | 6 | ||||
Income Tax | 64 | 64 | ||||||
Net Loss | $ | (14,285) | 4,394 | 1,448 | (8,443) | |||
Three months ended December 31, 2022 | ||||||||
GAAP | Stock-Based | Earn out | Non-GAAP | |||||
Cost of Revenues | $ | 4,077 | 7 | (1,255) | 2,829 | |||
Gross Profit | 2,732 | (7) | 1,255 | 3,980 | ||||
Research and development | 4,782 | (394) | (13) | 4,375 | ||||
Sales and Marketing | 3,920 | (953) | (53) | 2,914 | ||||
General and Administrative | 3,040 | (1,737) | 1,393 | 2,696 | ||||
Total Operating Expenses | 11,742 | (3,084) | 1,327 | 9,985 | ||||
Operating Loss | $ | (9,010) | 3,077 | (72) | (6,005) | |||
Financing income | 3,604 | - | 3,604 | |||||
Income Tax | 3 | 3 | ||||||
Net Loss | $ | (12,617) | 3,077 | (72) | (9,612) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Twelve months ended December 31, 2023 | ||||||||
GAAP | Stock-Based | Acquisition costs, | Non-GAAP | |||||
Cost of Revenues | $ | 14,368 | (327) | (4,490) | 9,551 | |||
Gross Profit | 5,984 | 327 | 4,490 | 10,801 | ||||
Research and development | 20,248 | (3,803) | (78) | 16,367 | ||||
Sales and Marketing | 23,785 | (6,468) | (171) | 17,146 | ||||
General and Administrative | 18,140 | (9,103) | (374) | 8,663 | ||||
Total Operating Expenses | 62,173 | (19,374) | (623) | 42,176 | ||||
Operating Loss | $ | (56,189) | 19,701 | 5,113 | (31,375) | |||
Financing expenses | 3,174 | - | - | 3,174 | ||||
Income Tax | 64 | 64 | ||||||
Net Loss | $ | (59,427) | 19,701 | 5,113 | (34,613) | |||
Twelve months ended December 31, 2022 | ||||||||
GAAP | Stock-Based | Earn out remeasurement, | Non-GAAP | |||||
Cost of Revenues | $ | 18,001 | (66) | (4,462) | 13,473 | |||
Gross Profit | 9,655 | 66 | 4,462 | 14,183 | ||||
Research and development | 19,649 | (3,608) | (46) | 15,995 | ||||
Sales and Marketing | 30,323 | (6,042) | (401) | 23,880 | ||||
General and Administrative | 16,493 | (7,259) | 569 | 9,803 | ||||
Total Operating Expenses | 66,465 | (16,909) | 122 | 49,678 | ||||
Operating Loss | $ | (56,810) | 16,975 | 4,340 | (35,495) | |||
Financing expenses | 5,379 | - | - | 5,379 | ||||
Income Tax | 4 | 4 | ||||||
Net Loss | $ | (62,193) | 16,975 | 4,340 | (40,878) | |||
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
Mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
Media Contact:
Scott Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/dariohealth-reports-fourth-quarter-and-full-year-2023-financial-and-operating-results-302102366.html
SOURCE DarioHealth Corp.
FAQ
What was DarioHealth Corp.'s full-year 2023 revenue?
What was the year-over-year growth in DarioHealth Corp.'s core B2B2C business?
What expenses decreased sequentially in Q4 2023 for DarioHealth Corp.?
What strategic milestone did DarioHealth Corp. achieve in Q1 of 2024?
What was the purpose of the acquisition of Twill, Inc. by DarioHealth Corp.?
